Panel: Differentiation or bust: How to stand out in a saturated market

As the cell and gene therapy industry becomes increasingly crowded, differentiation has become a non-negotiable for securing investment. With multiple companies pursuing similar approaches, investors are placing greater emphasis on identifying technologies that demonstrate a clear and defensible advantage.

• Why companies struggle to articulate what makes them different – and why this costs them deals
• Investor frameworks for distinguishing true breakthrough from incremental improvement – what they look for and what falls flat
• How founders can cut through a saturated market and make investors pay attention